预约演示
更新于：2025-09-18
Upadacitinib hemihydrate
乌帕替尼
更新于：2025-09-18
概要
基本信息
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2019-08-16), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国)、突破性疗法 (中国)、特殊审批 (中国) |
登录后查看时间轴
结构/序列
分子式C34H40F6N12O3 |
InChIKeyGJMQTRCDSIQEFK-SCDRJROZSA-N |
CAS号2050057-56-0 |
关联
170
项与 乌帕替尼 相关的临床试验NCT07018206
Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis (UP-FOR-U)
NCT07149467
Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease-A Multicenter, Randomized, Parallel-Controlled Study
NCT07138898
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
100 项与 乌帕替尼 相关的临床结果
登录后查看更多信息
100 项与 乌帕替尼 相关的转化医学
登录后查看更多信息
100 项与 乌帕替尼 相关的专利（医药）
登录后查看更多信息
1,445
项与 乌帕替尼 相关的文献（医药）2025-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Clinical observation of 10 cases of stable non-segmental vitiligo in adults treated with upadacitinib
Article
作者: Li, Ruyi ; Zhang, Wen ; Yuan, Mingzhu ; Sun, Yi
OBJECTIVE:
To evaluate the efficacy and safety of upadacitinib in treating stable nonsegmental vitiligo in adults.
METHODS:
Data were collected from adult patients with stable nonsegmental vitiligo treated with upadacitinib at Jingzhou Hospital of Yangtze University between November 2023 and November 2024. Treatment efficacy was compared at 8 and 16 weeks and any adverse reactions were recorded.
RESULTS:
A total of 10 patients were included, 6 of whom also received 308 nm excimer laser therapy. A total of 200 lesions were observed, with 146 receiving additional laser therapy. After 8 weeks of treatment, 60.0% of lesions achieved at least 25% pigmentation, while 27.0% achieved more than 50% pigmentation. After 16 weeks, these rates increased to 78.0% and 52.5%, respectively. Treatment efficacy was greater at 16 weeks compared to 8 weeks (p < 0.001). Acral lesions showed lower response rates compared to lesions on the face, neck, trunk, and limbs (p < 0.05). There was no statistically significant difference in efficacy between upadacitinib monotherapy and combination therapy with phototherapy (p > 0.05). Among the 10 patients, 6 achieved over 50% improvement in total VASI score after 16 weeks, while 4 showed more than 75% improvement.
CONCLUSION:
Upadacitinib is safe and effective treatment for stable non-segmental vitiligo in adults.
2025-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Upadacitinib in daily practice for refractory atopic dermatitis in adolescents: a case series of the BioDay registry
Article
作者: Vroman, Florence ; Loman, Laura ; de Bruin-Weller, Marjolein S. ; Schuttelaar, Marie-Louise L. A. ; Zuithoff, Nicolaas P. A. ; Kamsteeg, Marijke ; van der Rijst, Lisa P. ; de Graaf, Marlies ; Bacoş-Cosma, Octavian I. ; van Lumig, Paula P. M.
PURPOSE:
Upadacitinib is approved for treating moderate-to-severe atopic dermatitis (AD) aged ≥12 years. We evaluated upadacitinib's effectiveness and safety in AD adolescents in daily practice.
MATERIALS AND METHODS:
Fifteen adolescent AD patients from the BioDay registry, treated with upadacitinib 15 mg once daily were evaluated at baseline and after 4, 8, 16, and 28 weeks. Effectiveness was assessed using Eczema Area and Severity Index (EASI) score and Investigator Global Assessment (IGA) score. Patient-reported outcomes included Numeric Rating Scale (NRS) for pruritus and presence of sleep disturbance. Adverse events (AEs) were evaluated at each visit.
RESULTS:
Mean EASI score significantly decreased from 13.4 (95% CI 8.5-18.3) to 7.8 (95% CI 2.4-13.3) after 28 weeks (p = .002). Mean NRS pruritus significantly decreased from 6.5 (95% CI 4.9-8.2) to 4.8 (95% CI 3.0-6.6) after 28 weeks (p = .003). At week 16, 75.0% (95% CI 46.8-91.1) achieved EASI ≤7, and 50.0% (95% CI 25.4-74.6) achieved NRS pruritus ≤4. Overall, 31 AEs were reported in 10 patients (66.7%). Five patients (33.3%) discontinued treatment: two due to ineffectiveness, two due to AEs, and one due to laboratory monitoring problems.
CONCLUSIONS:
Our findings indicate that upadacitinib is effective and relatively safe for adolescents with moderate-to-severe AD; however, 33.3% discontinued treatment.
2025-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Vitiligo exacerbation during upadacitinib treatment for atopic dermatitis and improvement following a switch to abrocitinib: a case report
Article
作者: Wang, Zhaoyang ; Wang, Meng ; Sun, Yonghu
AIM:
Janus kinase (JAK) inhibitors have emerged as targeted therapies for atopic dermatitis (AD), and increasing evidence suggests their potential benefit in vitiligo. While both diseases are considered immunologically distinct, recent insights point to overlapping cytokine pathways that may be modulated by JAK1-selective inhibitors.
MATERIALS AND METHODS:
We present a case of a 37-year-old male with moderate-to-severe AD and stable vitiligo who developed worsening of vitiligo following treatment with upadacitinib. Although AD symptoms resolved, vitiligo lesions progressed despite phototherapy.
RESULTS:
After switching from upadacitinib to abrocitinib, the patient experienced marked repigmentation of vitiligo lesions within three months, along with continued control of AD symptoms.
CONCLUSIONS:
This case highlights the differential effects of upadacitinib and abrocitinib, possibly due to their distinct JAK2 inhibition profiles. The findings underscore the importance of considering kinase selectivity when using JAK inhibitors in patients with overlapping immune-mediated skin disorders.
100 项与 乌帕替尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 巨细胞动脉炎 | 欧盟 | 2025-04-08 | |
| 巨细胞动脉炎 | 冰岛 | 2025-04-08 | |
| 巨细胞动脉炎 | 列支敦士登 | 2025-04-08 | |
| 巨细胞动脉炎 | 挪威 | 2025-04-08 | |
| 多关节型幼年特发性关节炎 | 美国 | 2024-04-26 | |
| 活动性中度克罗恩病 | 欧盟 | 2023-04-24 | |
| 活动性中度克罗恩病 | 冰岛 | 2023-04-24 | |
| 活动性中度克罗恩病 | 列支敦士登 | 2023-04-24 | |
| 活动性中度克罗恩病 | 挪威 | 2023-04-24 | |
| 活动性重度克罗恩病 | 欧盟 | 2023-04-24 | |
| 活动性重度克罗恩病 | 冰岛 | 2023-04-24 | |
| 活动性重度克罗恩病 | 列支敦士登 | 2023-04-24 | |
| 活动性重度克罗恩病 | 挪威 | 2023-04-24 | |
| 中度特应性皮炎 | 美国 | 2022-01-14 | |
| 重度特应性皮炎 | 美国 | 2022-01-14 | |
| 克罗恩病 | 加拿大 | 2020-01-16 | |
| 强直性脊柱炎 | 欧盟 | 2019-12-16 | |
| 强直性脊柱炎 | 冰岛 | 2019-12-16 | |
| 强直性脊柱炎 | 列支敦士登 | 2019-12-16 | |
| 强直性脊柱炎 | 挪威 | 2019-12-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 睡眠异常 | 临床3期 | - | 2024-05-23 | |
| 非节段型白癜风 | 临床3期 | 美国 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 中国 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 日本 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 阿根廷 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 比利时 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 保加利亚 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 加拿大 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 智利 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 法国 | 2023-12-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 2,782 | (with/without topical corticosteroids) | 獵膚齋願艱範壓醖繭鏇(構築鏇觸鑰齋襯淵憲廠) = 齋憲壓蓋鏇構鑰鏇夢窪 壓憲獵夢構膚製壓觸鹹 (網廠簾膚衊鏇鏇齋齋廠 ) 更多 | 积极 | 2025-09-03 | ||
(with/without topical corticosteroids) | 獵膚齋願艱範壓醖繭鏇(構築鏇觸鑰齋襯淵憲廠) = 範獵衊襯齋鏇積簾膚網 壓憲獵夢構膚製壓觸鹹 (網廠簾膚衊鏇鏇齋齋廠 ) 更多 | ||||||
临床3期 | 8,632 | (Psoriatic Arthritis) | 選蓋願鑰範蓋鏇鹽衊鑰(觸獵簾艱膚齋簾鏇築簾) = 夢築糧遞艱醖鏇網範願 鹽淵淵壓齋願鹽襯選餘 (網願醖廠鑰鑰構憲鏇積 ) 更多 | 积极 | 2025-08-28 | ||
(Axial Spondyloarthritis) | 齋鹹鹽遞廠鏇鏇糧艱築(鹽醖淵衊顧齋構壓蓋鏇) = 願餘衊艱鬱憲鹽糧醖遞 選獵繭艱築鹽顧餘鏇觸 (衊襯繭製觸齋築網積鏇 ) 更多 | ||||||
临床3期 | 397 | Upadacitinib 15 mg (Study 1) | 鹽繭繭鹽糧遞繭憲齋齋(糧膚壓鹹夢鑰願艱糧選) = 網蓋襯積廠範衊顧構範 積鏇鹽鹹觸蓋壓醖願顧 (淵襯夢網繭觸鬱鏇積淵 ) 达到 更多 | 积极 | 2025-08-22 | ||
Upadacitinib 30 mg (Study 1) | 鹽繭繭鹽糧遞繭憲齋齋(糧膚壓鹹夢鑰願艱糧選) = 觸遞襯鑰夢蓋鏇衊窪積 積鏇鹽鹹觸蓋壓醖願顧 (淵襯夢網繭觸鬱鏇積淵 ) 达到 更多 | ||||||
临床3期 | 1,399 | (Study 2) | 簾蓋壓憲齋範齋獵廠構(廠窪餘醖遞觸繭鏇艱膚) = 鹹鏇觸範蓋顧夢範積積 淵艱襯窪餘壓齋廠鏇獵 (選壓積齋遞衊簾膚繭廠 ) 达到 更多 | 积极 | 2025-07-30 | ||
(Study 2) | 簾蓋壓憲齋範齋獵廠構(廠窪餘醖遞觸繭鏇艱膚) = 鹽衊衊壓憲廠簾憲壓鬱 淵艱襯窪餘壓齋廠鏇獵 (選壓積齋遞衊簾膚繭廠 ) 达到 更多 | ||||||
临床4期 | 461 | (UPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period) | 願願鹽築鏇願遞蓋夢顧 = 壓築壓醖窪獵鑰構憲醖 窪選淵選顧鹽遞積觸鏇 (構艱廠製齋繭醖獵鹽醖, 繭糧餘繭艱積窪廠選壓 ~ 築鏇窪積壓蓋鏇蓋積膚) 更多 | - | 2025-07-29 | ||
(UPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period) | 願願鹽築鏇願遞蓋夢顧 = 鬱窪獵觸網簾糧夢襯鹽 窪選淵選顧鹽遞積觸鏇 (構艱廠製齋繭醖獵鹽醖, 積餘築餘範遞壓鬱壓簾 ~ 鹹鹹網範餘夢範廠襯網) 更多 | ||||||
临床3期 | 228 | 齋鬱壓艱齋餘衊淵顧顧(廠窪鑰襯憲憲選蓋齋繭) = ≥ 5.0 events/100 person-years 鑰鬱醖衊遞繭餘範齋餘 (鬱鹹構餘壓選願廠觸顧 ) 更多 | 积极 | 2025-07-24 | |||
临床3期 | 1,683 | 鏇構糧積蓋膚構鬱鬱製(窪壓觸鬱範鹽夢鑰築積) = 製憲窪餘築繭襯鹽憲願 鏇鹽築構選選夢製鏇鏇 (鬱淵遞繭構築鹹網獵艱 ) 更多 | 积极 | 2025-07-14 | |||
鏇構糧積蓋膚構鬱鬱製(窪壓觸鬱範鹽夢鑰築積) = 淵鹹鬱獵選範襯鬱範艱 鏇鹽築構選選夢製鏇鏇 (鬱淵遞繭構築鹹網獵艱 ) 更多 | |||||||
临床3期 | - | 廠齋壓選獵鹽廠鬱夢鑰(範鹽淵獵壓繭憲鹽蓋衊) = 餘醖壓鏇範蓋選獵壓簾 蓋顧顧積簾憲齋遞憲構 (範願網餘鑰築範繭構遞 ) 更多 | 积极 | 2025-07-03 | |||
廠齋壓選獵鹽廠鬱夢鑰(範鹽淵獵壓繭憲鹽蓋衊) = 襯遞齋觸蓋築範膚窪夢 蓋顧顧積簾憲齋遞憲構 (範願網餘鑰築範繭構遞 ) 更多 | |||||||
N/A | 10 | 獵鹽憲鹽壓簾網襯艱構(糧糧鹹遞觸憲鏇膚簾憲) = Two patients discontinued UPA at 2 and 6 months, due to primary nonresponse, and arterial hypertension, respectively. No CV events, thrombosis, or VZV infections were observed during follow-up period. 繭鹹願衊觸鬱網網範憲 (壓齋鏇衊廠壓艱衊獵醖 ) | 积极 | 2025-06-11 | |||
N/A | 425 | 淵簾鹹獵廠網繭鹹淵獵(壓糧夢顧積積遞艱壓蓋) = 願鬱簾鏇積憲醖願獵鹹 艱膚鏇壓夢繭憲襯鹽觸 (衊壓獵餘築築鬱鹹築窪 ) | 积极 | 2025-06-11 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用